Immunovia has been approved for listing on Nasdaq Stockholm
First day of trading on Nasdaq Stockholm is scheduled for 3 April 2018, and the last day of trading on Nasdaq First North is scheduled for 29 March 2018. The share will continue to be traded under the same ticker (IMMNOV) and ISIN code (SE0006091997). The share will be subject to trading on Nasdaq Stockholm’s Small Cap segment. Shareholders of Immunovia do not need to take any actions in connection with the change of listing venue.
”Immunovias progress the last years has been tremendous and the admission to trade on the main list of NASDAQ Stockholm reflects that we transform from a development company to a diagnostic company with product sales. We regard the move to the regulated market to be very positive as it strengthens the brand, increases the recognition of the company and confirms the progress and maturity of Immunovia”, says Carl Borrebaeck, Chairman of the Board.
The prospectus that has been prepared in connection with the change of listing venue is expected to be approved by the Swedish Financial Supervisory Authority and published on Immunovia’s website, www.immunovia.com, on Tuesday 27 March at the latest.
The Company’s board of directors believes that a listing of the Company’s shares on Nasdaq Stockholm is a positive and important step in the development of Immunovia, which will further increase the awareness of Immunovia and strengthen its brand. Furthermore, the admission to trading on Nasdaq Stockholm is expected to satisfy the interest of institutional investors and give the Company greater access to the Swedish and international capital markets. For these reasons, the board of directors of Immunovia has made the assessment that a listing on Nasdaq Stockholm will support the Company’s next steps towards its long-term targets. In addition, a listing on Nasdaq Stockholm is expected to facilitate the Company’s growth strategy of organic nature, but also through potential acquisitions.
Baker McKenzie is Immunovia’s legal adviser in connection with the listing on Nasdaq Stockholm.
For more information, please contact:
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.